Table 1 Clinicopathological characteristics of trials included in this study
Study | Trial phase | Underlying malignancy | No. of patients enrolled | Median age (range), year | Gender (Male/ Female) | Treatment | Median treatment duration (range), month | Median follow-up (range), month |
|---|---|---|---|---|---|---|---|---|
Borghaei,2015 [6] | 3 | Lung cancer | 292 | 61(37–84) | 151/141 | Nivolumab 3 mg/kg every 14 days | 3.0(0.5–26.0) | > 13.2 |
290 | 64(21–85) | 168/122 | Docetaxel 75 mg/m2 every 21 days | 3.0(0.8–17.3) | ||||
Brahmer, 2015 [7] | 3 | Lung cancer | 135 | 62(39–85) | 111/24 | Nivolumab 3 mg/kg every 14 days | 4.0(0.5–24.0) | < 11.0 |
137 | 64(42–84) | 97/40 | Docetaxel 75 mg/m2 every 21 days | 2.3(0.8–21.8) | ||||
Carbone, 2017 [8] | 3 | Lung cancer | 271 | 63(32–89) | 184/87 | Nivolumab 3 mg/kg every 14 days | 3.7(0–26.9) | 13.5 |
270 | 65(29–87) | 148/122 | Chemotherapy once every 21 days | 3.4(0–20.9) | ||||
Ferris, 2016 [10] | 3 | Head and neck cancer | 240 | 59(29–83) | 197/43 | Nivolumab 3 mg/kg every 14 days | 1.9 | 5.1(0–16.8) |
121 | 61(28–78) | 103/18 | Systemic therapy single-agent | 1.9 | ||||
Kang, 2017 [9] | 3 | G/GJC | 330 | 62(54–69) | 229/101 | Nivolumab 3 mg/kg every 14 days | 1.9 | 8.9 |
163 | 61(53–68) | 119/44 | Placebo 3 mg/kg every 14 days | 1.9 | 8.6 | |||
Motzer, 2015 [11] | 3 | Renal cancer | 410 | 62(23–88) | 315/95 | Nivolumab 3 mg/kg every 14 days | 5.5(0–29.6) | > 14.0 |
411 | 62(18–86) | 304/107 | Everolimus 10 mg daily | 3.7(0.2–25.7) | ||||
Robert, 2015 [12] | 3 | Melanoma | 210 | 64(18–86) | 121/89 | Nivolumab 3 mg/kg every 14 days | NR | < 16.7 |
205 | 66(26–87) | 125/83 | Dacarbazine 1 g/m2 every 21 days | NR | ||||
Weber, 2017 [13] | 3 | Melanoma | 453 | 56(19–83) | 258/195 | Nivolumab 3 mg/kg every 14 days | 12.0 | > 18.0 |
453 | 54(18–86) | 269/184 | Ipilimumab 10 mg/kg every 21 days | 3.0 | ||||
Wolchok, 2017 [14] | 3 | Melanoma | 314 | 61(18–88) | 206/108 | Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 21 days | 6 | 38 |
316 | 60(25–90) | 202/114 | Nivolumab 3 mg/kg every 14 days | 7.5 | 35.7 | |||
315 | 62(18–89) | 202/113 | Ipilimumab 3 mg/kg every 21 days | 3 | 18.6 | |||
D’angelo, 2018 [15] | 2 | Sarcoma | 43 | 56(21–76) | 22/21 | Nivolumab 3 mg/kg every 14 days | 2.3 | 13.6 |
42 | 57(27–81) | 19/23 | Nivolumab 3 mg/kg + ipilimumab 1 mg/kg every 21 days | 3.7 | 14.2 | |||
Long, 2018 [16] | 2 | Melanoma | 35 | 59(53–68) | 29/6 | Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 21 days | NR | 14.0 |
25 | 63(52–74) | 19/6 | Nivolumab 3 mg/kg every 14 days | NR | 17.0 | |||
16 | 51(48–56) | 11/5 | Nivolumab 3 mg/kg every 14 days | NR | 31.0 | |||
Motzer, 2015 [19] | 2 | Renal cancer | 60 | 61 | 41/19 | Nivolumab 0.3 mg/kg every 21 days | 4.5(0–21.8) | > 24.0 |
54 | 61 | 40/14 | Nivolumab 2 mg/kg every 14 days | 5.6(0.8–24.0) | ||||
54 | 61 | 40/14 | Nivolumab 10 mg/kg every 14 days | 6.0(0.8–23.3) | ||||
Hamanishi, 2015 [18] | 2 | Ovarian cancer | 20 | 60(47–79) | 0/20 | Nivolumab 1 or 3 mg/kg every 14 days | 3.5(1.0–12.0) | 11.0(3.0–32) |
Hida, 2017 [29] | 2 | Lung cancer | 35 | 65(31–85) | 32/3 | Nivolumab 3 mg/kg every 14 days | 3.6(0.5–29.3) | < 30.0 |
Kudo, 2017 [30] | 2 | Esophageal cancer | 65 | 62(49–80) | 54/11 | Nivolumab 3 mg/kg every 14 days | 105(0.5–5.0) | 10.8 |
Maruyama, 2017 [31] | 2 | Hodgkin lymphoma | 17 | 63(29–83) | 13/4 | Nivolumab 3 mg/kg every 14 days | 7.0(1.4–10.6) | 9.8(6.0–11.1) |
Nishio, 2017 [32] | 2 | Lung cancer | 76 | 64(39–78) | 49/27 | Nivolumab 3 mg/kg every 14 days | NR | 16.6(0.9–31.9) |
Overman, 2017 [33] | 2 | Colorectal cancer | 74 | 53(44–64) | 44/30 | Nivolumab 3 mg/kg every 14 days | 11.0 | 12.0 |
Rizvi, 2015 [34] | 2 | Lung cancer | 117 | 65(57–71) | 85/32 | Nivolumab 3 mg/kg every 14 days | 2.3 | 8.0 |
Yamazaiki, 2017 [35] | 2 | Melanoma | 24 | 63(26–81) | 14/10 | Nivolumab 3 mg/kg every 14 days | 11.9(0.5–21.0) | 18.8(2.0–21.5) |
Younes, 2016 [36] | 2 | Hodgkin lymphoma | 80 | 37(28–48) | 51/29 | Nivolumab 3 mg/kg every 14 days | 8.5 | 8.9 |